FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

NCT04714372 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myeloid Leukemia
Monocytic Leukemia

Interventions

DRUG: Daratumumab/rHuPH20
DRUG: FT538
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Masonic Cancer Center, University of Minnesota